42 results about "Immune Cell Activation" patented technology

The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.

The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.

Groups of bi-specific binding domain constructs (BS-BDC) to treat cancer are described. Each BS-BDC in a group targets a cancer antigen epitope and an immune cell activating epitope that is different from the cancer antigen epitope and immune cell activating epitope targeted by another BS-BDC in the group. The different cancer antigen epitopes can be on the same cancer antigen.

The invention discloses an immune cell in-vitro induction amplification method in the related technical field of cell culture. The method comprises the following steps: producing a coated culture container; putting mononuclear cells of immune cells obtained by separation into the coated culture container, and carrying out immune cell activation culture for 24-36 h to obtain activated immune cells;preparing immune cells for induction amplification; differentiating and culturing to prepare differentiated immune cells; and preparing immune cells subjected to large-scale amplification, and performing passage once every 2-3 d under the condition of controlling the cell density to be 0.8-1.2 * 10<6 >/mL. The immune cell in-vitro induction amplification culture system is clear, and the amplification multiple is high; and the immune cells prepared by the immune cell in-vitro induction amplification method are good in immune effect, and the safety risk is effectively reduced.

The invention provides a macromolecular temperature-sensitive driver and a preparation method and application thereof. The macromolecular temperature-sensitive driver comprises targeting modules composed of polypeptide ligands, a driving module composed of a temperature-sensitive polymer, and triggering modules composed of photothermal conversion molecules, the triggering modules are connected to the targeting modules, and the targeting modules are connected to the driving module. The driver can be targeted to cell membrane protein by means of the polypeptide ligands, and can be effectively specifically combined with the membrane protein by way of active targeting of molecular recognition, the surface of the cell membrane is partially heated to activate the driver, so that the driver is collapsed and aggregated to generate pulling force, consequently, the assembly control of different membrane receptor proteins is realized, and a new effective strategy is provided for the research on signaling pathway, immunocyte activation, tumor treatment and the like.

The present invention encompasses methods of reducing inflammatory immune cell activation and inflammation via inhibiting mitochondrial fission.

The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.

This invention is related to a peptides mixture. Without the need to consider the patients' genetic background, it can interfere with MHC-pathogenic peptide-TCR formation, which includes the interference with pathogen peptide binding with MHC and pMHC binding with specific TCR, suppression of the immune synapse formation when the specific T cell immune response occurs, reduction of the number and density of the MHC-specific immune response mediated pathogenic peptide-TCR in the immune synapse, and suppression of the highly activated signal transduction in the immune synapse. Hence it can negatively regulate the T cell specific immune response, reduce the specific immune cell activation, proliferation and effect, and make the radical T cell specific immune response more stable and last longer. It can be used to treat diseases with excessive T cell-specific immune reaction, such as severe flu, SARS, hand-foot-and-mouth disease, viral pneumonia, bacterial infections, severe autoimmune disease and etc.

The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.

The present invention relates to a method for synthesizing α-galactoside epitope (α-Gal) on the surface of tumor cells and activating immune cells, using old, formalin-fixed or paraffin-embedded tumor specimens, through α-1,3-galactoside transferase catalyzes the synthesis of galactoside (α-Gal) epitopes on tumor cell membranes, enhances tumor antigenicity, and uses it as a vaccine. The α-Gal epitope on these tumor cell membranes can be phagocytized by antigen-presenting cells (APC) in vitro, activate T/CIK cells, and rapidly expand tumor-specific T/CIK cells in vitro. tumor cells.

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

The invention provides an immune cell in-vitro induced amplification, cryopreservation and resuscitation method, and relates to the technical field of immune cell in-vitro amplification. The immune cell in-vitro induced amplification, cryopreservation and resuscitation method mainly comprises the following steps: activating and culturing mononuclear cells by using an immune cell activation culture medium, performing primary induced amplification culture by using a primary amplification culture medium, performing secondary amplification culture by using a secondary amplification culture medium, performing cryopreservation treatment by using a cryopreservation solution, and mixing and unfreezing the cryopreservation solution. According to the present invention, the defects in the prior art are overcome, the induction efficiency of immune cells is effectively improved, the in-vitro amplification speed is high, the safety is high, and the cells still have good cell characteristics after being stored for a long time.

The invention provides an immunotherapy scheme for inhibiting tumors, especially solid tumors, T cells expressing chimeric CD3e fusion protein are combined with BiTA, the chimeric CD3e fusion proteinand BiTA are combined with each other, and the functions of activating the T cells and targeting tumor cells are exerted. The invention also provides a CAB structure and a CAB editing T cell (CAB-T).BiTA secreted by the CAB-T cells can simultaneously realize activation of the CAB-T cells and activation of endogenous TCR of the non-edited T cells in tumor tissues, and the anti-tumor effect of theCAB-T and the anti-tumor effect of mobilizing the non-edited T cells are exerted. The chimeric CD3e expressed by CAB-T and BiTA cooperate with each other to exert an anti-tumor effect: activation of the chimeric CD3e depends on BiTA secreted by CAB-T, and secretion of the BiTA further stimulates the CAB-T to release more BiTA by activating the chimeric CD3e; a small amount of BiTA released by CAB-T in tumor tissues can stimulate the CAB-T to release more BiTA by activating chimeric CD3e, so that immune cell activation and anti-tumor effects of tumor tissue tendency are realized, and the safetyadvantage of CAB-T clinical application is ensured.